Navigation Links
Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
Date:1/31/2008

cals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology, infectious diseases and other areas of unmet medical need. Tigris is currently conducting a Phase II clinical study for A-007, its topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV. Tigris is also developing three novel, targeted small molecule oncology compounds. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

Contact: Anne White

Chief Operating Officer

Tigris Pharmaceuticals, Inc.

(239) 444-5400

info@tigrispharma.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reim
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
2. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Amylin Pharmaceuticals Reports 2007 Financial Results
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... August 29, 2014 Dr. Parsa Mohebi M.D. ... of hair loss achieve great results in hair transplantation. ... Hair Transplant , an FUE method that harvests facial hair ... This method lets patients whose hair loss classification is 5 ... Transplant is a great alternative for those advanced hair loss ...
(Date:8/29/2014)... -- Astronauts may be at heightened risk of ... systems, a new study suggests. That could be ... the moon and Mars undertaken in the future, because ... be dangerous, NASA researchers say. They found that ... International Space Station crew members remains relatively unchanged during ...
(Date:8/29/2014)... 2014 Healthpointe Medical Group, one ... medical center from LAXMed. The medical center is less than ... miles west of the 405 freeway. , The LAX ... new LAX center is located at: 8610 S. Sepulveda Blvd., ... Healthpointe LAX office will provide the same comprehensive ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... Mayo Clinic review of patients responses to a drug ... general surgery questions a U.S. Food and Drug Administration ... appears in the current issue of the journal Anesthesiology. ... 2001 over concerns that the drug contributed to potentially ...
... This Decade ... OAKLAND, Calif., Sept. 28 Registered nurses at up to 16,Northern ... a major strike in October that could involve up to 5,500 ... Group in Yuba City and Marysville. Strike notices are being ...
... Center at Jefferson in Philadelphia have discovered new molecular ... breast cancer. They have found that prolactin, a pituitary ... initiates a new signaling pathway that may regulate the ... The work, which appears this month in the journal ...
... of William V. Corr, Executive Director, Campaign for,Tobacco-Free ... is a,statement of William V. Corr, Executive Director, ... will fall further behind in protecting,workers and the ... as two,more states - neighboring Maryland and Minnesota ...
... Insurance,Holdings, Inc. ("EIHI") (Nasdaq: EIHI ) announced ... Insurance Group ("EAIG") in the new position of,Regional ... an,indirect wholly-owned subsidiary of EIHI. EAIG entered ... licenses to underwrite in North Carolina, Virginia,Georgia and ...
... Cross,announces it has signed new three-year contracts with ... part of Catholic Health East health care,system, effective ... includes Mercy Fitzgerald Hospital, Mercy,Hospital of Philadelphia, Mercy ... Hospital, as well as Mercy Home Health and ...
Cached Medicine News:Health News:Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary 2Health News:RNs to Announce October Strike of 5,500 Nurses 2Health News:Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer 2Health News:Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit 2Health News:Eastern Alliance Insurance Group Appoints Cox Regional Marketing Director for Southeast 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 3
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Medina ... as CEO and member of the Board of Directors ... of medical device development and commercialization experience, including over ... Mr. Engelson previously served as a Partner of the ... President and CEO of two Foundry start-ups. Mr. Engelson ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... Administration (FDA) approved the use of once-daily INTUNIV® (guanfacine) ... treatment of attention deficit hyperactivity disorder (ADHD) in children and ... treatment program. The approval is based on results from a ...
... specialist in genome customization and subsidiary of Cellectis (Alternext: ... custom TALEN(1). Recognized as a pioneer in ... Cellectis bioresearch brings today the life sciences community a ... of cell. The service will start with ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Cellectis bioresearch Makes Genome Engineering Affordable for All Users 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: